Worldwide, more than 200 million people are at risk of losing their ability to walk due to lower-extremity arterial disease. Despite advances in modern medicine, maintaining durable blood flow in small-caliber below-the-knee vessels remains an unsolved challenge, with no definitive long-term solution to date.

We have established BioStealth™ Technology, a proprietary and world-leading approach designed to overcome this barrier. This highly original strategy—one that even major global corporations have yet to realize—represents the next milestone in the history of endovascular therapy.

We aim to answer the universal wish: “To keep walking for life.”